Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10137200 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(7 years from now) | |
US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US10086080 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US10517882 | JOURNEY | Method for healing of an infected acne lesion without scarring |
Oct, 2030
(7 years from now) | |
US10821187 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(7 years from now) | |
US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(7 years from now) | |
US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(7 years from now) | |
US10849847 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(14 years from now) | |
US10398641 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(14 years from now) |
Market Authorisation Date: 18 October, 2019
Treatment: Treatment of non-nodular acne vulgaris
Dosage: AEROSOL, FOAM;TOPICAL
59
United States
6
Canada
5
IB
2
Mexico
2
Australia
2
Israel
1
Brazil
1
China
1
South Africa
1
United Kingdom
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6682348 | ORAPHARMA | Dispensing apparatus and cartridge |
Mar, 2022
(1 year, 2 months ago) | |
US7699609 | ORAPHARMA | Dispensing apparatus and cartridge with deformable tip |
Mar, 2022
(1 year, 2 months ago) |
Market Authorisation Date: 16 February, 2001
Treatment: NA
Dosage: POWDER, EXTENDED RELEASE;DENTAL
3
United States
2
Australia
2
European Union
1
Canada
1
Colombia
1
Cyprus
1
Argentina
1
Slovenia
1
Brazil
1
Denmark
1
Portugal
1
Spain
1
Japan
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9278105 | REMPEX | Tetracycline compositions |
May, 2031
(7 years from now) | |
US9084802 | REMPEX | Tetracycline compositions |
May, 2031
(7 years from now) |
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INJECTION
8
United States
2
New Zealand
2
Spain
2
Japan
2
European Union
1
Colombia
1
Australia
1
Israel
1
Korea, Republic of
1
Canada
1
Denmark
1
Chile
1
Singapore
1
Portugal
1
Russia
1
Poland
1
Hong Kong
1
Mexico
1
Brazil
1
China
1
South Africa
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11103517 | EPI HLTH | Pharmaceutical compositions for minocycline |
Apr, 2036
(12 years from now) |
Market Authorisation Date: 08 May, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
2
United States
1
India
1
IB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8252776 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
US8722650 | BAUSCH | Extended-release minocycline dosage forms |
Jun, 2025
(2 years from now) | |
US8268804 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
US7790705 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
US7919483 | BAUSCH | Method for the treatment of acne |
Mar, 2027
(3 years from now) | |
US7541347 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(3 years from now) | |
US7544373 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(3 years from now) | |
US9192615 | BAUSCH | Method for the treatment of acne and certain dosage forms thereof |
Nov, 2031
(8 years from now) |
Market Authorisation Date: 08 May, 2006
Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris
Dosage: TABLET, EXTENDED RELEASE;ORAL
23
United States
2
Japan
1
Canada
1
China
1
South Africa
1
Australia
1
New Zealand
1
Norway
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7790705 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
US8252776 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
US8268804 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
US7919483 | JOURNEY | Method for the treatment of acne |
Mar, 2027
(3 years from now) | |
US7544373 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(3 years from now) | |
US7541347 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(3 years from now) |
Market Authorisation Date: 11 July, 2012
Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
23
United States
2
Japan
1
Canada
1
China
1
South Africa
1
Australia
1
New Zealand
1
Norway
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10946101 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(7 years from now) | |
US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(7 years from now) | |
US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(7 years from now) | |
US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US10322186 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) |
Market Authorisation Date: 28 May, 2020
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: AEROSOL, FOAM;TOPICAL
52
United States
5
Canada
5
IB
2
Australia
2
Israel
1
Mexico
1
Brazil
1
China
1
South Africa
1
United Kingdom
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic